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Abstract. There  are  many  genetic  and  acquired  risk  factors  that  are  known  to  cause  venous 
thromboembolic disorders (VTE). One of these is the Prothrombin G20210A mutation, which has 
been identified in 1996. Prothrombin
prothrombin  in  the  blood  of  carriers,  which  creates  a  higher  tendency  towards  blood  clotting 
(hypercoagulability), and therefore the carriers become at higher risk of developing VTE. High 
prevalence of  Prothrombin G20210A  mutation  was  reported in  Caucasian populations, but  the 
prevalence was almost absent in non
Europe  and  the  Mediterranean  region.  This  review  article  discusses  Prothrombin  G
mutation, how it causes VTE, the origin of the mutation, and its distribution worldwide with special 
concentration on the Mediterranean 
Introduction. Venous  thromboembolic  disorders 
(VTE)  are  serious  disorders  accounting  for  high 
morbidity and mortality rates with an annual incidence 
of  1/1000.
1-4 Many  genetic  and  acquired risk  factors 
were  identified  to  cause  VTE  including  Factor  V 
Leiden mutation, genetic deficiencies of proteins C, S 
and antithrombin, lupus anticoagulants, pregnancy, use 
of  contraceptives,  major  surgeries,  cancer, 
inflammations,  and  Prothrombin  G20210A  mutation. 
This review article focuses on Prothrombin G20210A 
mutation, its pathophysiology, prevalence and origin, 
with  a  special  concentration  on  this  mutation  in  the 
Mediterranean region. 
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There  are  many  genetic  and  acquired  risk  factors  that  are  known  to  cause  venous 
thromboembolic disorders (VTE). One of these is the Prothrombin G20210A mutation, which has 
been identified in 1996. Prothrombin G20210A mutation causes higher levels of the clotting factor 
prothrombin  in  the  blood  of  carriers,  which  creates  a  higher  tendency  towards  blood  clotting 
(hypercoagulability), and therefore the carriers become at higher risk of developing VTE. High 
ence of  Prothrombin G20210A  mutation  was  reported in  Caucasian populations, but  the 
prevalence was almost absent in non-Caucasians. That was most obvious in countries of South 
Europe  and  the  Mediterranean  region.  This  review  article  discusses  Prothrombin  G
mutation, how it causes VTE, the origin of the mutation, and its distribution worldwide with special 
concentration on the Mediterranean area.
s  thromboembolic  disorders 
(VTE)  are  serious  disorders  accounting  for  high 
morbidity and mortality rates with an annual incidence 
Many  genetic  and  acquired risk  factors 
were  identified  to  cause  VTE  including  Factor  V 
Leiden mutation, genetic deficiencies of proteins C, S 
and antithrombin, lupus anticoagulants, pregnancy, use 
of  contraceptives,  major  surgeries,  cancer, 
and  Prothrombin  G20210A  mutation. 
This review article focuses on Prothrombin G20210A 
mutation, its pathophysiology, prevalence and origin, 
with  a  special  concentration  on  this  mutation  in  the 
Role of Prothrombin in the Coagulation S
case  of  blood  vessel  injury,  blood  coagulation  is 
initiated  through  a  cascade  of  chemical  reactions  to 
form a blood clot to block the injured blood vessel and 
prevent  blood  loss.  Several  enzymes  and  proteins, 
generally known as blood clotting fac
in blood coagulation, a very important one is thrombin 
(clotting factor II). Thrombin is usually produced in the 
liver  in  an  inactive  form  called  prothrombin,  which 
circulates in the blood until being activated in case of 
injury.  Potrhombin  gets  activated  into  thrombin  by 
another clotting factor called activated factor X. The 
main  function  of  thrombin  is  to  convert  fibrinogen 
(clotting  factor  I)  into  a  fibrin  clot  that  blocks  the 
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G20210A mutation causes higher levels of the clotting factor 
prothrombin  in  the  blood  of  carriers,  which  creates  a  higher  tendency  towards  blood  clotting 
(hypercoagulability), and therefore the carriers become at higher risk of developing VTE. High 
ence of  Prothrombin G20210A  mutation  was  reported in  Caucasian populations, but  the 
Caucasians. That was most obvious in countries of South 
Europe  and  the  Mediterranean  region.  This  review  article  discusses  Prothrombin  G20210A 
mutation, how it causes VTE, the origin of the mutation, and its distribution worldwide with special 
Role of Prothrombin in the Coagulation System. In 
case  of  blood  vessel  injury,  blood  coagulation  is 
initiated  through  a  cascade  of  chemical  reactions  to 
form a blood clot to block the injured blood vessel and 
prevent  blood  loss.  Several  enzymes  and  proteins, 
generally known as blood clotting factors, are involved 
in blood coagulation, a very important one is thrombin 
(clotting factor II). Thrombin is usually produced in the 
liver  in  an  inactive  form  called  prothrombin,  which 
circulates in the blood until being activated in case of 
bin  gets  activated  into  thrombin  by 
another clotting factor called activated factor X. The 
main  function  of  thrombin  is  to  convert  fibrinogen 
(clotting  factor  I)  into  a  fibrin  clot  that  blocks  the Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
injured blood vessel. In fact, thrombin is a very robust 
enzyme  that  plays  a  major  role  in  the  coagulation 
system by activating many clotting factors and other 
elements  of  the  coagulation  system  like  the  blood 
platelets. Thrombin is usually under careful monitoring 
by an inhibitor called antithrombin (AT), which down-
regulates  thrombin  after  clot  formation  and  prevents 
accidental formation of thrombin in  sites  away from 
injured  vessels.
5,6 This  is  very  crucial  to  prevent the 
formation  of  unnecessary  clots  inside  intact  blood 
vessels.  The  formation  of  such  intravascular  clots 
predisposes to the development of VTE.  
Prothrombin  G20210A  Mutation.  Because  of  the 
importance  of  thrombin  in  the  coagulation  system, 
genetic or acquired deficiency of prothrombin usually 
causes  impaired  clotting  and  therefore  bleeding 
problems (hemophilia). On the contrary, if prothrombin 
is  produced in higher quantities in  the blood, this is 
expected to cause an increased tendency towards blood 
clotting,  a  condition  known  as  “hypercoagulability”, 
which usually manifests clinically as VTE. It has been 
demonstrated that prothrombin levels more than 115% 
of  the  normal  level  have  2-fold  increased  risk  of 
developing  VTE.
7 Poort  et  al  (1996)  performed  an 
extensive  DNA sequencing on  the  prothrombin gene 
(on  chromosome  11)  for  patients  with  unexplained 
VTE.
7 They found a single missense mutation (guanine 
to adenine; GA) at nucleotide position 20210, which 
is  present  in  the  3′  untranslated  region  of  the 
prothrombin  gene.  This  Prothrombin  G20210A 
mutation  is  present  outside  the  coding  region  for
prothrombin,  and  hence  it  does  not  affect  the  actual 
structure of the prothrombin molecule and it does not 
affect  its  function  as  a  strong  clotting  factor  when 
activated  into  thrombin.  However,  Prothrombin 
G20210A mutation was found to cause elevated levels 
of blood  prothrombin  (by  one-third  above  normal; 
133%), which is more than the extra 15% needed to 
develop VTE.  Also,  it  has  been  proven  that 
Prothrombin  G20210A  mutation leads  to  increased 
mRNA  and protein  expression  for  prothrombin.
8
Table 1. Prevalence of Prothrombin G20210A mutation in different populations and countries worldwide.
Region/Country VTE
patients %
Healthy 
population % References
Caucasians
North Europe
(UK, Ireland, Sweden, Finland, Belarus, Russia, 
Denmark, Netherlands, Poland, Germany) 
6.5 0-2.9 16-26
South Europe 
(France, Austria, Spain, Switzerland, Hungary, Italy, 
Slovenia, Croatia, Serbia, Greece, Turkey, Cyprus)
2.7-17.2 0.7-8.0 16,17, 
28-67
USA 3.2-9.7 1.3-5.0 68-71
Brazil --- 1.7 72
Australia --- 4.3 73
Israel --- 4.0 74
Africans
Ivory Coast, Central Africa Republic, Madagascar, 
Kenya, Mali --- 0 75
Zaire, Cameron --- 0 72
USA 1.1-2.2 0-0.3 68,69,70,
71,76,77
Israel  --- 0 74
Brazil --- 0 72
Hispanics USA 8.9 0.5-2.4 68,70
Mexican 
Mestizos
Mexico 13.5-15.0 78,79
Asians
China 0 0 80,81
Japan --- 0 72,82,83
Korea 0 0 68,84,85
Mongolia --- 0 75
Taiwan 0 0 75,86,87
Southeast Asia
(Indonesia, Burma, Cambodia, Thailand, Taiwan, 
Vietnam, Hong Kong
--- 0 75
India 0 0-0.6 68,75,88-92
Pakistan, Bangladesh --- 0 88
Native 
Americans 
(Amerind-
ians)
USA --- 0 68
Canada --- 0 75
Brazil --- 0 72,75
Mexico --- 0 75
Australian 
Aboriginals Australia --- 0 93
Austral-asians Papua New Guinea, Vanuatu, Tonga, Micronesia  --- 0 75Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
Moreover, increased prothrombin levels may lead to an 
increase  in  a  protein  called  thrombin-activatable 
fibrinolysis inhibitor (TAFI), which is an inhibitor of 
the fibrinolysis process. Fibrinolysis is the process by 
which the blood removes clots. Therefore, an increase 
in  TAFI  may  disturb  the  fibrinolysis  process  and 
therefore  allow  for  accumulation  of  clots  leading  to 
VTE.
9,10 This  is  another  possible  pathophysiological 
pathway of causing VTE in cases having Prothrombin 
G20210A  mutation  with  elevated  TAFI.  All  these
findings  may  explain  why  Prothrombin  G20210A 
mutation  may  cause  hypercoagulability  and  an 
increased risk of developing VTE. Such increased risk 
was reported to be 2 to 4-fold.
7,11-15
Prevalence of Prothrombin G20210A mutation. The 
prevalence  of  Prothrombin  G20210A  mutation  in 
European Caucasians was found to be roughly 3-17% 
in  patients  with  VTE  and  1-8%  in  healthy  controls. 
That was also true in Caucasians living outside Europe 
like in the USA, Australia, Brazil and Israel (Table 1). 
It  may  be  noticed  here  that  the  prevalence  of 
Prothrombin  G20210A  mutation  is  higher  in  the 
Southern  European  countries  than  in  the  Northern 
countries, in spite of presence of overlapping between 
the North and South. On the other hand, Prothrombin 
G20210A mutation was found to be very rare or even 
absent in Asian and African populations, and in native 
populations  of  America  (Amerindians)  and  Australia 
(Table 1). This was also true when these populations 
were  studied  in  countries  outside  their  origin  like 
African Americans and Asians living in the USA. The 
only exception to the above observations is the high 
prevalence  reported  in  Hispanics  and  Mexican 
Mestizos; the latter are descendants of mixed marriages 
between Europeans and Amerindians. The presence of 
European genes in such populations may explain the 
high prevalence of Prothrombin G20210A mutation in 
these.  
High prevalence of Prothrombin G20210A mutation 
was also reported in populations living close to Europe, 
namely countries of the Middle East and North Africa. 
In  fact,  the  prevalence  in  these  countries  was  very 
comparable with the prevalence reported in Southern 
European countries. Therefore, the countries present on 
the  coasts  of  the  Mediterranean  Sea,  including 
Southern Europe, may be grouped together sharing the 
same  prevalence  of  Prothrombin  G20210A  mutation 
(Table  2).  These  countries,  20  in  total,  have  a 
prevalence of 3-24% in patients with VTE and 1-12% 
in the general population. No reports could be found in 
Malta,  Syria,  Bosnia,  Albania  and  Macedonia.  The 
highest prevalence was found by a study in Egypt in 
patients with VTE, but the highest among the general 
populations  (healthy  controls)  was  in  Palestinians 
living  in  Israel  (Israeli  Arabs).  Unfortunately,  there 
were  no  reports  on  the  prevalence  in  Palestinian 
patients with VTE, which kight be higher than the one 
reported in Egypt, noting that Egypt and Palestine are 
geographically neighbours.  
Table  2. Prevalence  of  Prothrombin  G20210A  mutation  in  the 
Mediterranean countries.
Country VTE 
patients %
General healthy 
population %
References
Lebanon 19.2 1.3-3.6 94-99
Palestine --- 6.5-11.7 74,100
Egypt 23.75 3.33 101
Tunisia 3.2 0-7.4 74,79-
99,102-105
Libya --- 2.2 74
Algeria 6.0 1.8 106
Morocco --- 2.4-5.5 74,107-109
Spain 2.7-17.2 2.9-6.5 31-35
France 4.6 1.0-3.1 36-39
Italy 4.3-15.9 2.3-5.7 40-47
Slovenia 5.8-11.3 3.1-4.8 48,49
Croatia 8.0-8.3 2.5-4.0 50-53
Serbia 11.4 2.3-6.0 54-56
Greece 6.8-10.1 2.0-2.7 57-61
Turkey 4.0-10.5 0.7-8.0 62-65
Cyprus --- 2.0-7.8 66,67
Origin  of  Prothrombin  G20210A  mutation.  The 
highest prevalence of Prothrombin G20210A mutation 
in  European Caucasians brought up speculations that 
Prothrombin G20210A mutation might have occurred 
as a single event in a single Caucasian ancestor and 
that  the  current  Caucasian  carriers  of  the  mutation 
should  have  descended  from  that  proposed 
grandparent.  This  assumption  was  supported  by  a 
molecular study that found a haplotype to be associated 
with more than two third of carriers of the mutation 
compared to one third of non-carriers. This suggests a 
founder effect, and the mutation was estimated to occur 
around 24 thousand years ago after the divergence of 
Africans  from  Non-Africans  and  Caucasoids  from 
Mongoloids.
110 It is  tempting  to  explore this  founder 
haplotype in non-Caucasian carriers of the Prothrombin 
G20210A  mutation  in  the  Middle  East  and  North 
Africa to see if this founder effect occurred there too. 
In addition, it may be interesting to study this mutation 
in the Basque population (in France and Spain), who is 
thought to be the oldest ethnic group living in Europe. 
Finding or not finding the mutation in this population 
may give a hint on the origin of the mutation and to 
know if it occurred inside or outside Europe. Also, if a 
future  study  can  prove  that  Palestinian  patients  with 
VTE  have  the  highest  prevalence  of  Prothrombin 
G20210A  mutation  (like  the  general  Palestinian 
population), then this region (Palestine/Israel) may be 
the  place  where the  mutation  has  occurred and  then 
spread to Europe and other parts of the Mediterranean 
region.  This  region  has  witnessed  a  lot  of  mankind Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
movements  since  the  old  ages,  since  the  Neolithic 
period,  and  then  the  Phoenicians  who  appeared  in 
Lebanon  and  then  cruised  to  many  cities  on  the 
Mediterranean  coast,  followed  by  the  Roman  and 
Greek  civilizations, and  more  recently  the  Crusaders 
and  Ottomans.  Therefore, it  is  encouraging to  try  to 
find certain genetic or chromosomal markers that can 
help in following the migratory history of manhood in 
the  Mediterranean  region  which  may  give  a  final 
approach  towards  determining  exactly  where  the 
mutation has occurred first and how it spread all over 
the Mediterranean region. 
Conclusions.  The  prevalence  of  Prothrombin 
G20210A  mutation  differs  in  different  countries  and 
ethnic groups, being highest in Caucasians, especially 
those in the Southern Europe, and in the Mediterranean 
region.  Further  studies  are  needed  to  verify  where 
exactly has the mutation occurred first and how it was 
carried to other parts of the world. 
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